Human ApoC-III transgenic (dyslipidemic) mouse, healthy cynomolgus monkey and dyslipidemic rhesus macaque
“In vivo pharmacological characterization of plozasiran was conducted in a transgenic mouse expressing human ApoC-III (human ApoC-III mouse), healthy cynomolgus monkey, and dyslipidemic rhesus macaque monkeys.”
Antisense strand fully complementary to monkey and human ApoC-III mRNA but has seven mismatches to rat
“The antisense strand of plozasiran is designed to be fully complementary to the monkey and human ApoC-III mRNA transcripts whereas seven sequence mismatches exist with the rat ApoC-III mRNA sequence.”
EMA: in vivo PD response demonstrated by liver APOC3 suppression, lower serum APOC3 and lipid-lowering effects
“Regarding the primary pharmacology of plozasiran, it can be concluded that the in vivo PD response of plozasiran was shown by the suppression of liver APOC3 expression, reduction in serum APOC3 protein concentrations and lipid-lowering effects in serum.”